Unmixed Monoclonal Antibody Bevacizumab
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) for therapeutic use in cancer treatment. It falls under HTS 3002.13.0090 as an unmixed immunological product not put up in measured doses or retail packaging, directly involved in regulating immunological processes. This classification applies to bulk biotech-derived antibodies for further pharmaceutical processing.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If put up in measured doses or retail packings
Products in final consumer-ready forms shift to 3002.14, excluding bulk preparations for further mixing.
If classified primarily as a hormone or steroid derivative rather than immunological
Certain biotech products with hormone-like structures may fall under Chapter 29 if not primarily immunological per chapter notes.
If specifically antisera rather than other immunological products
Antisera have distinct classification from other blood fractions or monoclonal antibodies.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Verify FDA biologics license and provide certificates of analysis confirming purity and biotech origin to avoid misclassification as Chapter 29 chemicals
• Ensure cold chain documentation (2-8°C) during import to maintain product integrity, as deviations can lead to customs holds
• Declare exact concentration and absence of excipients to confirm 'unmixed' status; common pitfall is classifying diluted solutions under 3002.14
Related Products under HTS 3002.13.00.90
Bulk Rituximab Immunological Product
Rituximab is a chimeric monoclonal antibody targeting CD20 on B-cells, used in lymphoma and autoimmune disease therapy. Classified under HTS 3002.13.0090 as an unmixed immunological product obtained via biotechnological processes, supplied in bulk for formulation. It regulates immunological processes as defined in chapter notes.
Unmixed Infliximab Biosimilar
Infliximab biosimilar is a monoclonal antibody binding TNF-alpha, used for inflammatory conditions like rheumatoid arthritis. HTS 3002.13.0090 covers it as an unmixed, biotech-derived immunological product not in retail form. It qualifies per chapter notes as a protein regulating immunological processes.
Bulk Trastuzumab Emtansine Conjugate
Trastuzumab emtansine is an antibody-drug conjugate (ADC) with monoclonal antibody linked to chemotherapy agent for HER2-positive breast cancer. Classifies as unmixed immunological product in HTS 3002.13.0090 per notes covering antibody conjugates. Bulk form excludes retail packaging.
Adalimumab High-Concentration Solution
Adalimumab is a fully human monoclonal antibody against TNF for autoimmune diseases like psoriasis. As an aqueous solution of unmixed product, it qualifies under HTS 3002.13.0090 per chapter notes treating dissolved unmixed products similarly. Bulk for further dilution.
Bulk Pembrolizumab
Pembrolizumab is a PD-1 inhibitor monoclonal antibody for immuno-oncology applications. Classifies in HTS 3002.13.0090 as unmixed biotech immunological product regulating immune checkpoint processes. Not for retail sale.
Nivolumab Drug Substance
Nivolumab drug substance is bulk PD-1 blocking antibody for melanoma and lung cancer therapy. HTS 3002.13.0090 for unmixed immunological products via biotech processes. Meets definition of antibody regulating immunology.